This brand name is authorized in South Africa
The drug EFALITH contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Lithium succinate
UNII MD64P82Y28 - DILITHIUM SUCCINATE
|
|
Little is known about the way the lithium ion can modify neurotransmission within the CNS. Many of the proposed mechanisms have suggested an inhibitory effect on components of various neurotransmitter signalling pathways, such as cyclic AMP formation, cyclic GMP formation, G-proteins or inositol phosphate metabolism. |
|
2
Zinc sulfate
UNII 89DS0H96TB - ZINC SULFATE, UNSPECIFIED FORM
|
|
Zinc sulfate is a source of zinc which is an essential trace element and involved in a number of body enzyme systems. Severe deficiency causes skin lesion, alopecia, diarrhoea, increased susceptibility to infections and failure to thrive in children. |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ZA | Health Products Regulatory Authority | Identifier(s): Z/13.4.2/245 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
